The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Open accessAbstract
Purpose: BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods: A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results: BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Ostrom, Q. T., Gittleman, H., Fulop, J., Liu, M., Blanda, R., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov189 · Cited by 2,139
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationPacker, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., Jakacki, R., Kurczynski, E., Needle, M., Finlay, J., et al. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.5.0747 · Cited by 636
Self-citationAter, J. L., Zhou, T., Holmes, E., Mazewski, C. M., Booth, T. N., Freyer, D. R., Lazarus, K. H., Packer, R. J., Prados, M., Sposto, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.6054 · Cited by 433
Self-citationQaddoumi, I., Orisme, W., Wen, J., Santiago, T., Gupta, K., Dalton, J. D., Tang, B., Haupfear, K., Punchihewa, C., Easton, J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1539-z · Cited by 409
Self-citationActivating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
Self-citationMistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Self-citationSievert, A. J., & Fisher, M. J. (2009) · Journal of Child Neurology · doi:10.1177/0883073809342005 · Cited by 285
BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma
Hawkins, C., Walker, E., Mohamed, N., Zhang, C., Jacob, K., Shirinian, M., Alon, N., Kahn, D., Fried, I., Scheinemann, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0034 · Cited by 250
Self-citationPhase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
Bouffet, E., Jakacki, R., Goldman, S., Hargrave, D., Hawkins, C., Shroff, M., Hukin, J., Bartels, U., Foreman, N., Kellie, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.5843 · Cited by 233
Self-citationKrishnatry, R., Zhukova, N., Guerreiro Stucklin, A. S., Pole, J. D., Mistry, M., Fried, I., Ramaswamy, V., Bartels, U., Huang, A., Laperriere, N., et al. (2016) · Cancer · doi:10.1002/cncr.29907 · Cited by 173
Self-citationBRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma
Dahiya, S., Haydon, D. H., Alvarado, D., Gurnett, C. A., Gutmann, D. H., & Leonard, J. R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1120-y · Cited by 169
Jacob, K., Quang-Khuong, D.-A., Jones, D. T. W., Witt, H., Lambert, S., Albrecht, S., Witt, O., Vezina, C., Shirinian, M., Faury, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0127 · Cited by 168
Self-citationInterplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas
Horbinski, C., Nikiforova, M. N., Hagenkord, J. M., Hamilton, R. L., & Pollack, I. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos077 · Cited by 149
Brainstem Ganglioglioma Successfully Treated With Vemurafenib
Rush, S. Z., Foreman, N. K., & Liu, A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1568 · Cited by 129
Self-citationRyall, S. T., Krishnatry, R., Arnoldo, A., Buczkowicz, P., Mistry, M., Siddaway, R., Ling, C., Pajovic, S., Yu, M., Rubin, J. B., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0353-0 · Cited by 121
Self-citationTreatment implications of the emerging molecular classification system for melanoma
Romano, E., Schwartz, G. K., Chapman, P. B., Wolchock, J. D., & Carvajal, R. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70274-6 · Cited by 100
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
Bufalo, F. D., Carai, A., Figà-Talamanca, L., Pettorini, B. L., Mallucci, C. L., Giangaspero, F., Antonelli, M., Badiali, M., Moi, L., Bianco, G., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0356-1 · Cited by 95
Pediatric low-grade gliomas: How modern biology reshapes the clinical field
Bergthold, G., Bandopadhayay, P., Bi, W. L., Ramkissoon, L. A., Stiles, C. D., Segal, R. A., Beroukhim, R., Ligon, K. L., Grill, J., & Kieran, M. W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.004 · Cited by 76
Self-citationAlhejaily, A., Day, A. G., Feilotter, H. E., Baetz, T. D., & LeBrun, D. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2175 · Cited by 69
Pilomyxoid astrocytoma treated successfully with vemurafenib
Skrypek, M. M., Foreman, N. K., Guillaume, D., & Moertel, C. L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25084 · Cited by 58
Self-citationSuccessful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib
Aguilera, D. G., Janss, A. J., Mazewski, C., Castellino, R. C., Schniederjan, M., Hayes, L. L., Brahma, B., Fogelgren, L., & MacDonald, T. J. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25787 · Cited by 53
Bergthold, G., Bandopadhayay, P., Hoshida, Y., Ramkissoon, S. H., Ramkissoon, L. A., Rich, B. E., Maire, C. L., Paolella, B. R., Schumacher, S. E., Tabak, B., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov045 · Cited by 52
Self-citationBerg, M., Nordgård, O., Kørner, H., Oltedal, S., Smaaland, R., Søreide, J. A., & Søreide, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122391 · Cited by 34
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Fangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507
Self-citationIntegrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Self-citationAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Self-citationPediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Self-citation
Metadata
- Authors
- Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., Ling, C., McKeown, T., Loukides, J., Cruz, O., de Torres, C., Ho, C.-Y., Packer, R. J., Tatevossian, R., Qaddoumi, I., Harreld, J. H., Dalton, J. D., Mulcahy-Levy, J., Foreman, N., Karajannis, M. A., Wang, S., Snuderl, M., Nageswara Rao, A., Giannini, C., Kieran, M., Ligon, K. L., Garre, M. L., Nozza, P., Mascelli, S., Raso, A., Mueller, S., Nicolaides, T., Silva, K., Perbet, R., Vasiljevic, A., Faure Conter, C., Frappaz, D., Leary, S., Crane, C., Chan, A., Ng, H.-K., Shi, Z.-F., Mao, Y., Finch, E., Eisenstat, D., Wilson, B., Carret, A. S., Hauser, P., Sumerauer, D., Krskova, L., Larouche, V., Fleming, A., Zelcer, S., Jabado, N., Rutka, J. T., Dirks, P., Taylor, M. D., Chen, S., Bartels, U., Huang, A., Ellison, D. W., Bouffet, E., Hawkins, C., & Tabori, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-09-01
- Volume
- 35
- Issue
- 25
- Pages
- 2934-2941
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2737907665
- Cited by
- 349
- References
- 28
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.